UPDATE: Plainview Says We are short $FGEN and believe $FGEN's ASN 2019 pres on Fri Nov 8 will show lead drug roxadustat failed to achieve key endpt of MACE non-inferiority in DD-CKD/NDD-CKD'
Benzinga Newsdesk